Renal outcomes of radioligand therapy: experience of 177lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer.

Autor: Gallyamov, Marat1 (AUTHOR) Marat.Gallyamov@genesiscare.com, Meyrick, Danielle1 (AUTHOR), Barley, Jerome1 (AUTHOR), Lenzo, Nat1,2 (AUTHOR)
Zdroj: Clinical Kidney Journal. Dec2020, Vol. 13 Issue 6, p1049-1055. 7p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje